A case study of a patient with progressive pancreatic cancer singles out T-cell receptor transduction therapy as a promising new approach for others with the same mutation and the right allele.
/PRNewswire/ ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, today announces.
- Data published in the Journal of ImmunoTherapy of Cancer confirms efficacy of combination treatment (anti-PD1 + ISA101b) - Deep and durable responses have a profound positive effect
/PRNewswire/ ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, today announces.
First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals Lead Immunotherapy ISA101b with Keytruda®
Combination aimed at priming and driving durable patient immune responses to cancer
News provided by
Share this article
Share this article
LEIDEN, The Netherlands, Jan. 26, 2021 /PRNewswire/ ISA Pharmaceuticals B.V., a clinical-stage company dedicated to developing rationally designed immunotherapeutics for oncology and infectious disease, today announced that the first patient has been dosed with its lead product ISA101b in a Phase II trial conducted and sponsored by UPMC Hillman Cancer Center, the University of Pittsburgh, PA, and supported by Merck Sharp & Dohme Corp and ISA Pharmaceuticals B.V.